<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181610</url>
  </required_header>
  <id_info>
    <org_study_id>2001P001475</org_study_id>
    <nct_id>NCT00181610</nct_id>
  </id_info>
  <brief_title>Recombinant Human Prolactin for Lactation Induction</brief_title>
  <official_title>Recombinant Human Prolactin for Lactation Induction in Mothers of Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and determine the effects of the hormone
      prolactin on lactation (breast milk production).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blind, placebo controlled trial. Subjects will be admitted
      to the General Clinical Research Center (GCRC) as outpatients to undergo their baseline
      pumping study. One lactation consultant will educate all subjects in the proper technique for
      pumping on the first day of the study and will evaluate their technique on day 5 and day 8 of
      the study. The lactation consultant will also instruct patients to record the volume of milk
      pumped and the time of each pumping episode. Subjects will be encouraged to have direct
      contact with their infants prior to pumping. All infant contact, infant latching onto the
      breast and mother's stress level will also be recorded throughout the study. Starting at 8 am
      on day 1, a hospital grade breast pump will be used to drain both breasts as confirmed by the
      absence of milk flow for 2 min during each episode of pumping and by palpation. Pumping will
      be performed in this manner every 3 hours around the clock. Subjects will be allowed a 5 hour
      window to sleep, however, as long as the total number of pumping episodes equals 8 in 24
      hours.

      During the first episode of pumping, a baseline prolactin level will be drawn immediately
      before the start of a pumping and repeated at 10 min intervals for 60 min, and then every 30
      min for a total of 3 hours to document the peak prolactin level. An intravenous line will be
      placed to draw blood. Subsequently, subjects will be randomized to receive prolactin or
      placebo. On the morning of days 2, 5 and 8, blood will be collected for a prolactin level
      before medication injection. Subsequently, prolactin 60 mg/kg or placebo will be injected
      subcutaneously by the study nurse 3 hrs after the last pumping episode. On days 2 and 8,
      additional blood will be collected every 10 min for the first hour, every 30 min for hour 2
      and 3, then at 4, 6 and 8 hours after injection to determine the peak prolactin level during
      a pumping session. Subjects will then drain both breasts as confirmed by the absence of milk
      flow for 2 min during each episode of pumping and by palpation and milk volume recorded. The
      subjects' vital signs will be monitored immediately before and every 15 minutes for 1 hr,
      every 30 min for hours 2 and 3, and then at 4, 6 and 8 hours after injection of
      prolactin/placebo. Temperature will be measured before the injection, every hour for hours 2
      and 3, and then at 4, 6 and 8 hours after injection of placebo/prolactin. If there are no
      changes in vital signs, on days 5 and 8 vital signs will be monitored at baseline, only.
      Subjects will be taught to do SC injections on their own and will administer their second
      dose of SC r-hPRL or placebo 12 hours after the first dose. Subjects will continue every 12
      hour SC r-hPRL or placebo administration for the next 7 days. Subjects will be asked to
      refrigerate all milk and bring it in to GCRC visits so that the volume that is recorded can
      be confirmed and for testing the milk composition and prolactin level before it is given to
      the infants. The final prolactin injection will be given on the evening of study day 8. All
      side effects in the mother and baby will be recorded daily throughout the study. Subjects
      will return for a final outpatient visit on day 16, to determine if any treatment effect
      persists. During this visit, milk will be pumped at baseline and volume recorded. In
      addition, blood will be drawn at 10 min intervals for 60 min, and then every 30 min for a
      total of 3 hours to document the peak prolactin level. Subjects will turn in their pumping
      diary the next day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Breast Milk Volume Baseline to 7 Days</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Milk Prolactin Levels</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Lactation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo group normal saline twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human prolactin 60 mcg/kg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Prolactin</intervention_name>
    <description>60 mcg/kg every 12 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human prolactin</intervention_name>
    <description>60 mcg/kg given every 12 hours or every 24 hours</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>twice per day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women, aged 18-45 years

          -  Lactation insufficiency postpartum

          -  Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are
             pumping breast milk for their infant's nutritional support and to maintain their milk
             supply.

          -  Subjects will have given birth at a gestational age of at least 24 weeks, and will
             generally be recruited 4-8 weeks postpartum.

        Exclusion Criteria:

          -  Medications known to increase prolactin

          -  Anatomical breast abnormalities

          -  Use of medication contraindicated in breastfeeding mothers

          -  Allergies to mannitol

          -  Current use of hormonal contraception

          -  Previous mammoplasty or breast augmentation, unless they have successfully nursed an
             infant for 3 months in the past without requiring supplemental formula.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrine K Welt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 5, 2013</results_first_submitted>
  <results_first_submitted_qc>May 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2013</results_first_posted>
  <last_update_submitted>December 31, 2017</last_update_submitted>
  <last_update_submitted_qc>December 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Corrine Welt</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lactation</keyword>
  <keyword>Breastfeeding</keyword>
  <keyword>Premature infants</keyword>
  <keyword>Prolactin</keyword>
  <keyword>Primary lactation insufficiency</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2004-2008 Academic Hospital, clinical research center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Twice Per Day</title>
          <description>Placebo group
Normal Saline : twice per day</description>
        </group>
        <group group_id="P2">
          <title>Recombinant Human Prolactin Twice Per Day</title>
          <description>Recombinant human prolactin every 12 hours
Recombinant Human Prolactin : 60 mcg/kg every 12 hours</description>
        </group>
        <group group_id="P3">
          <title>Recombinant Human Prolactin Alternating With Placebo</title>
          <description>Recombinant human prolactin alternating with placebo every 12 hours
Recombinant human prolactin : 60 mcg/kg given every 24 hours alternating with normal saline placebo given once every 24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject did not complete the study and data was not analyzed for that subject.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Twice Per Day</title>
          <description>Placebo group
Normal Saline : twice per day</description>
        </group>
        <group group_id="B2">
          <title>Recombinant Human Prolactin Twice Per Day</title>
          <description>Recombinant human prolactin every 12 hours
Recombinant Human Prolactin : 60 mcg/kg every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Recombinant Human Prolactin Once Per Day</title>
          <description>Recombinant human prolactin alternating with placebo every 12 hours
Recombinant human prolactin : 60 mcg/kg given every 12 hours or every 24 hours</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="5"/>
                    <measurement group_id="B2" value="30" spread="5"/>
                    <measurement group_id="B3" value="32" spread="6"/>
                    <measurement group_id="B4" value="32" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Breast Milk Volume Baseline to 7 Days</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Twice Per Day</title>
            <description>Placebo group
Normal Saline : twice per day</description>
          </group>
          <group group_id="O2">
            <title>Recombinant Human Prolactin Twice Per Day</title>
            <description>Recombinant human prolactin every 12 hours
Recombinant Human Prolactin : 60 mcg/kg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Recombinant Human Prolactin Alternating With Placebo</title>
            <description>Recombinant human prolactin alternating with placebo every 12 hours
Recombinant human prolactin : 60 mcg/kg given every 24 hours Placebo given every 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Breast Milk Volume Baseline to 7 Days</title>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="27"/>
                    <measurement group_id="O2" value="429" spread="338"/>
                    <measurement group_id="O3" value="44" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Milk Prolactin Levels</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Twice Per Day</title>
            <description>Placebo group
Normal Saline : twice per day</description>
          </group>
          <group group_id="O2">
            <title>Recombinant Human Prolactin Twice Per Day</title>
            <description>Recombinant human prolactin every 12 hours
Recombinant Human Prolactin : 60 mcg/kg every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>Recombinant Human Prolactin Alternating With Placebo</title>
            <description>Recombinant human prolactin alternating with placebo every 12 hours
Recombinant human prolactin : 60 mcg/kg given every 24 hours alternating with normal saline placebo given once every 24 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Milk Prolactin Levels</title>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="13"/>
                    <measurement group_id="O2" value="118" spread="25"/>
                    <measurement group_id="O3" value="118" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Twice Per Day</title>
          <description>Placebo group
Normal Saline : twice per day</description>
        </group>
        <group group_id="E2">
          <title>Recombinant Human Prolactin Twice Per Day</title>
          <description>Recombinant human prolactin every 12 hours
Recombinant Human Prolactin : 60 mcg/kg every 12 hours</description>
        </group>
        <group group_id="E3">
          <title>Recombinant Human Prolactin Once Per Day</title>
          <description>Recombinant human prolactin alternating with placebo every 12 hours
Recombinant human prolactin : 60 mcg/kg given every 12 hours or every 24 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Red marks</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corrine Welt, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-8437</phone>
      <email>cwelt@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

